Ecopipam Treatment of Tourette's Syndrome in Subjects 7-17 Years

This study is currently recruiting participants. (see Contacts and Locations)
Verified April 2016 by Psyadon Pharma
Information provided by (Responsible Party):
Psyadon Pharma Identifier:
First received: March 31, 2014
Last updated: April 14, 2016
Last verified: April 2016
Tourette's Syndrome is a neurological disease characterized by motor and vocal tics. It has been hypothesized that abnormal interactions of dopamine with its receptors may cause the tics. The purpose of this study is to test the hypothesis that a drug (ecopipam) that selectively blocks dopamine D1/D5 receptors can reduce the frequency and severity of the tics.

Condition Intervention Phase
Tourette's Syndrome
Drug: Ecopipam
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Crossover Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Ecopipam Treatment of Tourette's Syndrome in Subjects 7-17 Years

Resource links provided by NLM:

Further study details as provided by Psyadon Pharma:

Primary Outcome Measures:
  • Yale Global Tic Severity Scale [ Time Frame: 30 days ] [ Designated as safety issue: No ]
    The Yale Global Tic Severity Scale (YGTSS) is the standard rating scale used to assess the effects of a new treatment on the symptoms of Tourette's Syndrome.

Secondary Outcome Measures:
  • Safety [ Time Frame: 30 days ] [ Designated as safety issue: Yes ]
    Safety will be assessed by monitoring and recording all Adverse Events (AE) and serious adverse events (SAE), regular monitoring of hematology, blood chemistry, and urine values, regular measurement of vital signs and the performance of a physical examination and an ECG

  • DuPaul ADHD rating scale-IV [ Time Frame: 30 days ] [ Designated as safety issue: No ]
    This is a validated rating scale for the symptoms of attention deficit disorder. This is included because people with Tourette's often have attention deficit hyperactivity disorder (ADHD) as well.

  • Child Yale-Brown Obsessive Compulsive Scale [ Time Frame: 30 days ] [ Designated as safety issue: No ]
    This is validated rating scale which measures symptoms of obsessive-compulsive behaviors. People with Tourette's often also show symptoms of obsessive-compulsive behaviors.

  • Children's Depression Inventory [ Time Frame: 30 days ] [ Designated as safety issue: Yes ]
    The Children's Depression Inventory is a validate rating scale which measures signs of depression of in children. People with Tourette's often report feelings of depression. In addition, treatment with ecopipam has been reported to increase signs of depression in some patients.

  • Clinical Global Impression - Improvement and Severity Scales [ Time Frame: 30 days ] [ Designated as safety issue: No ]
    Clinical Global Impression Scales (improvement and severity) are validated rating scales that measure whether the treatment improves the symptoms of the disease (CGI-I) and whether the treatment reduces the severity of the disease (CGI-S)

  • Columbia-Suicide Severity Rating Scale [ Time Frame: 30 days ] [ Designated as safety issue: Yes ]
    The Columbia Suicide Severity Rating Scale is a validated rating scale which measures feelings of suicide.

Estimated Enrollment: 30
Study Start Date: March 2014
Estimated Study Completion Date: December 2017
Estimated Primary Completion Date: December 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Ecopipam
Ecopipam is a selective antagonist of the dopamine D1/D5 receptor family that is being studied as a treatment for Tourette's Syndrome
Drug: Ecopipam
Ecopipam is a selective antagonist of the dopamine D1 receptor family.
Other Names:
  • SCH 39166
  • PSYRX101
Placebo Comparator: Placebo
Placebo is the inactive comparator
Drug: Ecopipam
Ecopipam is a selective antagonist of the dopamine D1 receptor family.
Other Names:
  • SCH 39166
  • PSYRX101

Detailed Description:
This is a double blind, randomized, placebo-controlled crossover study to determine whether ecopipam can reduce the symptoms of Tourette's in children age 7-17 years.

Ages Eligible for Study:   7 Years to 17 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:• Subjects must have Tourette's Syndrome (TS) based on the clinician-administered Diagnostic Confidence Index (DCI) for TS.

  • Subjects must exhibit both motor and vocal tics.
  • Subjects must have a minimum score of 20 at both Screening and Baseline (just prior to the first treatment) on the Yale Global Tic Severity Scale.
  • Subjects must be age (≥ 7 to < 18 years of age)
  • Subjects must weigh ≥ 20 kg (45 lbs)
  • Adolescent females of childbearing potential who are sexually active must be using effective contraception (i.e., oral contraceptives, intrauterine device, double barrier method of condom and spermicide) and agree to continue use of contraception for the duration of their participation in the study. They must also agree to use contraception for 30 days after their last dose of study drug.
  • Sexually active male subjects must use a barrier method of contraception during the study and agree to continue the use of male contraception for at least 30 days after the last dose of study drug.
  • Subject's parent or legal guardian must execute a written informed consent.
  • Subject must execute a written informed assent.

Exclusion Criteria:

  • Subjects who have unstable medical illness or clinically significant abnormalities on laboratory tests, or ECG at Screening.
  • Subjects with a major depressive episode in the past 2 years
  • Subjects with a history of attempted suicide
  • Subjects with clinically significant suicidality (based on the Columbia Suicide Rating Scale (C-SSRS)
  • Subjects with a first-degree relative with a major depressive episode that resulted in any psychiatric hospitalization, or attempted/ completed suicide with the exception of a hospitalization for post-partum depression.
  • Subjects with a history of seizures (excluding febrile seizures that occurred >2 years in the past)
  • Subjects with a myocardial infarction within 6 months.
  • Girls who are currently pregnant or lactating.
  • Subjects who have a need for medication (other than ecopipam) with possible effects on TS symptoms (i.e., lithium, psychostimulants)
  • Subjects who have a need for medications which would have unfavorable interactions with ecopipam, e.g., dopamine antagonists or agonists [including bupropion], tetrabenazine, or monoamine oxidase inhibitors.
  • Subjects with a lifetime history of bipolar disorder type I or II, dementia, schizophrenia, or any psychotic disorder determined by the Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders - 4th Edition (DSM-IV) Axis-I Disorders (SCID).
  • Subjects with current or recent (past 3 months) DSM-IV substance abuse or dependence (with the exception of nicotine).
  • Subjects with positive urine drug screen (cocaine, amphetamine, methamphetamine, tetrahydrocannabinol (THC), benzodiazepines, barbiturates, phencyclidine (PCP), opiates) at Screening. Subjects with urine positive only for benzodiazepines and/or marijuana (i.e., a user but not an abuser as based on DSM-IV criteria) may be eligible.
  • Subjects who have had previous treatment with ecopipam.
  • Subjects who have had treatment with:

    • investigational medication within 3 months of starting study
    • depot neuroleptics within 3 months of starting study
    • other psychotropics with possible effects on TS symptoms (i.e., lithium, tetrabenazine) within 2 weeks prior to Screening.
    • oral neuroleptics within 4 weeks
    • selective serotonin reuptake inhibitors unless the dosage has been stable for a minimum of 4 weeks prior to study start and not prescribed to relieve the neurological signs of TS
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT02102698

Contact: Richard Chipkin, PhD 301-919-2020

United States, California
UCLA Recruiting
Los Angeles, California, United States, 90024
Contact: Jennifer Cowen, EdD    310-825-6170   
Principal Investigator: James McCracken, MD         
United States, Florida
University of South Florida/Rothman Center for Neuropsychiatry Recruiting
St. Petersburg, Florida, United States, 33701
Contact: Tanya Murphy, MD    727-767-8230   
Contact: Alexis Wolfe    727-767-7238   
Principal Investigator: Tanya Murphy, MD         
United States, Georgia
Emory University School Of Medicine Recruiting
Atlanta, Georgia, United States, 30322
Contact: Jorge Juncos, MD    404-728-4952   
Contact: Cathy Wood-Siverio, BS   
Principal Investigator: Jorge Juncos, MD         
United States, Illinois
University of Chicago Medical School Recruiting
Chicago, Illinois, United States, 60637
Contact: Jon Grant, MD    773-834-1325   
Contact: Sarah Redden, BA    773-702-9066   
United States, Kansas
Children's Mercy Kansas City Recruiting
Kansas City, Kansas, United States, 64108
Contact: Keith Coffman, MD    816-234-3090   
Contact: Gloria Womelduff    816-234-3492   
United States, Missouri
Washington University School of Medicine Recruiting
St. Louis, Missouri, United States, 63110
Contact: Kevin Black, MD    314-362-6281   
Contact: Nicole Bauer    314.747.3064   
United States, New Jersey
Overlook Hospital Recruiting
Summit, New Jersey, United States, 07902
Contact: Roger Kurlan, MD    908-522-2089   
Contact: Caroline Sabatino, BS    (908) 522-5901   
Principal Investigator: Roger Kurlan, MD         
United States, New York
North Shore-Long Island Jewish Hosptial Recruiting
Manhasset, New York, United States, 11030
Contact: Cathy L Budman, MD    516-562-3223   
Contact: Ray Susan, MS    (516) 562-3641   
Principal Investigator: Cathy L Budman, MD         
Weill Cornell Medical School Recruiting
New York City, New York, United States, 10065
Contact: Justin Mohatt, MD    646-962-2820   
Contact: Lucia Haladjian    (212) 746-5930   
United States, Ohio
Cincinnati Children's Hospital Recruiting
Cincinnati, Ohio, United States, 45228
Contact: Donald Gilbert, MD    513-636-0599   
Contact: Mary Fisher    513-803-0127   
Principal Investigator: Donald Gilbert, MD         
United States, Texas
Baylor College of Medicine Recruiting
Houston, Texas, United States, 77030
Contact: Jankovic Joseph, MD    713-798-5998   
Contact: Farah Ismail, BS    713-798-6629   
Principal Investigator: Joseph Jankovic, MD         
Sponsors and Collaborators
Psyadon Pharma
Study Chair: Donald Gilbert, MD Children's Hospital Medical Center, Cincinnati
  More Information

Responsible Party: Psyadon Pharma Identifier: NCT02102698     History of Changes
Other Study ID Numbers: PSY302 
Study First Received: March 31, 2014
Last Updated: April 14, 2016
Health Authority: United States: Food and Drug Administration

Keywords provided by Psyadon Pharma:
Tourette's Syndrome
D1 Receptor
Phase 2

Additional relevant MeSH terms:
Tourette Syndrome
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Genetic Diseases, Inborn
Heredodegenerative Disorders, Nervous System
Mental Disorders
Mental Disorders Diagnosed in Childhood
Movement Disorders
Nervous System Diseases
Neurodegenerative Diseases
Pathologic Processes
Tic Disorders
Antipsychotic Agents
Central Nervous System Agents
Central Nervous System Depressants
Dopamine Agents
Dopamine Antagonists
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Pharmacologic Actions
Physiological Effects of Drugs
Psychotropic Drugs
Therapeutic Uses
Tranquilizing Agents processed this record on April 27, 2016